Experimental combo for liver cancer shows early promise, but trial halted
NCT ID NCT06320080
First seen Nov 21, 2025 · Last updated Apr 29, 2026 · Updated 19 times
Summary
This early-stage study tested a new drug (TQB2223) combined with an immunotherapy (penpulimab) in 22 people with advanced liver cancer. The goal was to see if the combination could shrink tumors or slow the disease. The trial was terminated early, so results are limited. Participants had to be in relatively good health despite advanced cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, 150000, China
-
Hubei Provincial Tumor Hospital
Wuhan, Hubei, 430079, China
-
Hunan Provincial Tumor Hospital
Changsha, Hunan, 410031, China
Conditions
Explore the condition pages connected to this study.